{"id":"NCT01556165","sponsor":"H. Lundbeck A/S","briefTitle":"Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China","officialTitle":"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2013-12","completion":null,"firstPosted":"2012-03-16","resultsPosted":"2014-12-23","lastUpdate":"2014-12-23"},"enrollment":130,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"rasagiline","otherNames":["Azilect"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"rasagiline","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Rasagiline has been developed for the treatment of Parkinson's Disease (PD), as monotherapy in early PD patients not treated with levodopa, and as adjunct therapy to levodopa in levodopa-treated PD patients with motor fluctuations.\n\nThe rationale for conducting this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in Chinese PD patients not treated with levodopa.","primaryOutcome":{"measure":"Change From Baseline to Week 26 in UPDRS Total Score","timeFrame":"Baseline to Week 26","effectByArm":[{"arm":"Placebo","deltaMin":-0.18,"sd":0.98},{"arm":"Rasagiline","deltaMin":-3.18,"sd":0.95}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0254"}]},"eligibility":{"minAge":"35 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":15,"countries":["China"]},"refs":{"pmids":["30534374"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":65},"commonTop":["Parkinson's disease","Accidental overdose"]}}